HFN Login and Registration
LOGIN PASSWORD
Need Help? Register here
Skip Navigation Links
Home
About HFN
News
Funds
Investor Tools
Manager Services
Data Services
Research
Service Providers
Conferences
Help
HedgeFund.net: Public news from HedgeNews
Sign Up for the HFN Daily Newsletter         |    Take a Tour of the HFN Website    |    Register      |         Login
Hedgefund.net Register Here
Click below for information on membership options
Premium Access Manager Services Data Services
Asset Flow Report View Front Page  

Garden State Hedge Backing Up Icahn
by Christopher Glynn ,Senior Reporter, February 10, 2009

A New Jersey hedge fund is seconding Carl Icahn in his call for a shakeup at a faltering drug company.

DellaCamera Capital Management, based in Bridgewater, N.J., is a 7% shareholder of Enzon Pharmaceuticals, which corporate raider Icahn has been battling since 2008.

Ichan is pushing to gain a presence on the Enzon board. Billionaire Icahn has also bashed Jeff Buchalter, chief executive officer of the company, for his salary.

For its part, DellaCamera Capital is also pressing the company to fire Wall Street firm Goldman Sachs as its financial adviser. The hedge fund firm is blaming Goldman Sachs for an ill advised convertible bond offering, supporting a spinoff, selling a business unit and presiding over a bungled Dutch auction.

Biotechnology is a big sector for Icahn. Aside from Enzon, he has agitated Mylan Laboratories to nix a deal for King Pharmaceuticals. He is the chairman of Imclone.

Lawyer Andrew Kurtz is the head of DCM. He worked for Guggenheim Capital, co-founded Spectrum Investment Partners and served as a portfolio manager for Elliott Management, the New York activist shareholder. In addition to Enzon, the hedge fund firm in 2009 has pressured Curagen Corp.

  
Recent Articles 
Poll Of the Week
  Poll of the Week
by HedgeNews Editors , January 28, 2010
 
 
1 Comments
Post a comment.
POSTED BY Christopher Glynn at 2/10/2009 1:40:55 PM
Add your Comments:
 Name: Required
 Email: Required(will not be published)
All comments will be reviewed for appropriateness, length and lucidity.
 
 

Disclaimer: An affiliated broker-dealer of HedgeFund.net is compensated for providing capital introduction services to hedge funds and hedge fund managers, which may include one or more hedge funds mentioned in this article. Hedge funds and/or hedge fund managers mentioned in this article also may compensate HedgeFund.net for services provided to them by HedgeFund.net













 HOME    HEDGEPLUS    HEDGENEWS    PORTFOLIOS    FUNDS    PERTRAC              Copyright 2010, Channel Capital Group Inc. All Rights Reserved.   
NEITHER CHANNEL CAPITAL GROUP INC.("CCG"),ITS AFFILIATES,OR CCG'S OR ITS AFFILIATES RESPECTIVE OFFICERS,DIRECTORS,AGENTS,MEMBERS,SHAREHOLDERS AND EMPLOYEES (EACH A "CCG PARTY" AND COLLECTIVELY THE "CCG PARTIES")RECOMMENDS OR SOLICITS ANY INVESTMENT BY USERS OF THIS WEB SITE,THE MATERIAL CONTAINED HEREIN IS BASED UPON INFORMATION PROVIDED BY HEDGE FUND MANAGERS AND OTHER SOURCES. THE CCG PARTIES HAVE NOT INDEPENDENTLY VERIFIED SUCH INFORMATION,DO NOT REPRESENT IT AS ACCURATE ,TRUE OR COMPLETE, MAKE NO WARRENTY, EXPRESS OR IMPLIED REGARDING IT AND SHALL NOT BE LIABLE FOR ANY LOSSED,DAMAGES,COSTS, OR EXPENSES RELATING TO ITS ADEQUANCY ,ACCURACY ,TRUTH ,COMPLETENESS, OR USE, REGISTERED USERS SHOULD NOT RELY UPON DATA TO MAKE AN INVESTMENT DECISION ,AND SHOULD NOT THAT PAST PERFORMANCE IS NOT AN INDICATION OF FUTURE.